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Abstract
BACKGROUND—Acellular pertussis vaccines replaced whole-cell vaccines for the 5-dose 
childhood vaccination series in 1997. A sixth dose of pertussis-containing vaccine, tetanus toxoid, 
reduced diphtheria toxoid, and acellular pertussis, adsorbed (Tdap), was recommended in 2005 for 
adolescents and adults. Studies examining Tdap vaccine effectiveness (VE) among adolescents 
who have received all acellular vaccines are limited.
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METHODS—To assess Tdap VE and duration of protection, we conducted a matched case-
control study during the 2012 pertussis epidemic in Washington among adolescents born during 
1993–2000. All pertussis cases reported from January 1 through June 30, 2012, in 7 counties were 
included; 3 controls were matched by primary provider clinic and birth year to each case. 
Vaccination histories were obtained through medical records, the state immunization registry, and 
parent interviews. Participants were classified by type of pertussis vaccine received on the basis of 
birth year: a mix of whole-cell and acellular vaccines (1993–1997) or all acellular vaccines (1998–
2000). We used conditional logistic regression to calculate odds ratios comparing Tdap receipt 
between cases and controls.
RESULTS—Among adolescents who received all acellular vaccines (450 cases, 1246 controls), 
overall Tdap VE was 63.9% (95% confidence interval [CI]: 50% to 74%). VE within 1 year of 
vaccination was 73% (95% CI: 60% to 82%). At 2 to 4 years postvaccination, VE declined to 34% 
(95% CI: −0.03% to 58%).
CONCLUSIONS—Tdap protection wanes within 2 to 4 years. Lack of long-term protection after 
vaccination is likely contributing to increases in pertussis among adolescents.
Despite high childhood and adolescent vaccination coverage, >48 000 pertussis cases were 
reported in the United States in 2012, the greatest number reported since 1955.1 In addition, 
there were new and concerning changes in the age distribution of pertussis cases, with 
increasing incidence among fully vaccinated children and adolescents within a few years of 
vaccination.1–3
Although infants <1 year of age continue to have the highest rates of pertussis, increased 
rates among 7- to 10-year-olds were recently observed.3 Notably, this cohort of children was 
among the first to receive solely acellular pertussis vaccines for the childhood series. Waning 
immunity after vaccination with diphtheria-tetanus-acellular pertussis (DTaP) vaccines 
appears to be a major contributing factor for increased disease risk.4–6
Because tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis, adsorbed (Tdap) 
was recommended for adults and adolescents only in 2006, studies estimating Tdap vaccine 
effectiveness (VE) and duration of protection are few. Several observational studies noted an 
overall VE range of 64% to 78% within 2 years of vaccination.7–10 To our knowledge, only 
1 study has measured Tdap duration of protection for >2 years, and it concluded that VE 
waned over time.11
In 2012, Washington State declared a pertussis epidemic with nearly 5000 cases reported. 
An unexpectedly high disease incidence was seen in adolescents 13 to 14 years of age 
despite Tdap coverage of 86%.2,12 The emergence of disease in this age group had not been 
observed since the introduction of Tdap, raising concerns for waning immunity after the 
Tdap dose in adolescents who received all acellular pertussis vaccines as children. The 
epidemic in Washington provided an opportunity to estimate Tdap VE and duration of 
protection among the first cohort of adolescents who received all acellular vaccines.
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METHODS
Study Oversight
This evaluation was conducted as part of the public health response to the 2012 Washington 
pertussis epidemic and was determined to be nonresearch program evaluation by the Centers 
for Disease Control and Prevention Human Research Protection Office and the Washington 
State Department of Social and Health Services Institutional Review Board.
Study Design and Population
To estimate Tdap VE and duration of protection, we conducted a matched case-control 
study. The 7 Washington counties reporting >50 cases among adolescents during the study 
period of January 1 to June 30, 2012, agreed to participate (Clark, King, Pierce, Skagit, 
Snohomish, Yakima, and Whatcom).
The study included adolescents 11 to 19 years of age, born from January 1, 1993, through 
December 31, 2000. We included all suspected, probable, and confirmed pertussis cases 
reported among residents of the 7 participating counties during the study period. Cases were 
classified by using the Council of State and Territorial Epidemiologists case definitions for 
probable and confirmed pertussis cases.13 A clinical case was defined as cough for ≥14 days 
with at least 1 of the following symptoms: whoop, posttussive vomiting, or paroxysmal 
cough. A confirmed case was defined as cough illness of any duration plus isolation of 
Bordetella pertussis from a clinical specimen or a clinical case with either a positive 
polymerase chain reaction test result or contact with a laboratory-confirmed case 
(epidemiologic link). Clinical cases that were not laboratory-confirmed or epidemiologically 
linked to a laboratory-confirmed case were classified as probable cases. The Washington 
State Department of Health also included a suspected case category defined as a positive 
polymerase chain reaction test result with illness not meeting the clinical case definition.14
We selected 3 controls for each case, matched by birth year and primary provider clinic. 
Controls were randomly selected from a clinic-generated patient roster that included all 
adolescents born in the same year as the case and who had at least 1 clinic visit since 2005. 
Potential controls were excluded and replaced with another randomly selected control if the 
provider suspected or diagnosed pertussis during the study period, the patient had been 
discharged from the clinic, the patient had an out-of-state home zip code, or patient medical 
records were unavailable. The symptom onset date of the case was used as the enrollment 
date for each case and associated matched controls.
Demographic information (date of birth, gender, home zip code, ethnicity, race) and 
vaccination histories for cases and controls were collected at provider clinics by using a 
standardized protocol and medical chart abstraction form. Vaccination date, product, 
manufacturer, and lot number were recorded for all documented pertussis-, diphtheria-, or 
tetanus-containing vaccines, including the childhood series and adolescent dose when 
available. To verify brand, we matched available lot numbers for the childhood series and 
adolescent dose with known lot numbers provided by the Washington State Department of 
Health and 2 pertussis vaccine manufacturers (GlaxoSmithKline, Brentford, United 
Kingdom; Sanofi Pasteur, Swiftwater, PA).
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We supplemented provider vaccination histories with information from the Washington State 
Immunization Information System.15 If vaccination history was available in both sources but 
discrepant, provider records were used as the definitive source. If Tdap vaccination status 
remained unknown after reviewing these sources, parents or guardians were contacted to 
verify Tdap vaccine receipt.
The childhood series was considered complete and on schedule if the participant had 
documentation in the provider records or immunization registry of 5 doses of 
diphtheriatetanus toxoids-pertussis (DTP) or DTaP meeting the following criteria: doses 1 
through 3 before the first birthday, dose 4 on or after the first birthday and before the second 
birthday, and dose 5 on or after the fourth birthday and before the seventh birthday.16
We classified participants as vaccinated if a Tdap vaccination date was confirmed in the 
provider records, the immunization registry, or by parent interview. We classified 
participants as unvaccinated if no record of Tdap vaccination date was found in the provider 
records or the immunization registry and Tdap nonreceipt was confirmed by a parent. In 
addition, participants were classified as unvaccinated if Tdap receipt was confirmed but the 
vaccination occurred after the enrollment date or if Tdap was received within 2 weeks before 
the enrollment date. We considered a participant’s vaccination status to be unknown if a 
Tdap vaccination date was not documented in the provider records or the immunization 
registry and the parent interview was inconclusive.
The Washington State Childhood Vaccination Program has been the sole distributor of 
childhood and adolescent vaccines to public and private health care providers since the early 
1990s.17,18 We reviewed available vaccine distribution data and determined that the 
transition of whole-cell to acellular pertussis vaccines for the complete childhood series 
occurred during 1997, after which we assumed that whole-cell vaccines were no longer 
available. We verified this assumption by cross-checking study-obtained lot numbers against 
manufacturer data.
To evaluate the impact of the whole-cell or acellular pertussis childhood vaccination series 
on Tdap VE, study participants were stratified on the basis of birth year into 2 groups. The 
acellular group included adolescents born from 1998 to 2000 and were assumed to have 
received all acellular pertussis vaccines for the childhood series, whereas the mixed group 
included those born from 1993 to 1997 and were assumed to have received a mix of whole-
cell and acellular pertussis vaccines.
Statistical Analysis
To estimate the association between pertussis and Tdap receipt, we used conditional logistic 
regression to calculate odds ratios, accounting for matching factors (provider and birth year). 
VE was calculated as: 1 − odds ratio × 100%. Tdap-unvaccinated participants were the 
reference group in all models. We estimated duration of protection by measuring the 
association between pertussis and time since Tdap vaccination (<12 months, 12–23 months, 
24–47 months).
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We excluded cases and controls if Tdap vaccination status was unknown, or if there was 
documentation of inadvertent administration of DTaP during adolescence, Tdap before the 
age of 10 years, or ≥2 Tdap doses. In addition, controls were excluded if they had ever been 
reported to the Washington State Department of Health as having pertussis.
The primary analysis measured Tdap VE and duration of protection in study participants 
who received all acellular pertussis vaccines for the childhood series (birth years 1998–
2000; ages 11–14 years). Additional subgroup analyses assessed the stability of the VE 
estimates by restricting the analysis to those with confirmed and probable case status, those 
with confirmed case status only, or those with a complete and on-schedule childhood series. 
We also evaluated Tdap VE among participants who received a mix of whole-cell and 
acellular vaccines (birth years 1993–1997; ages 15–19 years), as well as differences in VE 
by Tdap product.
Statistical comparison of demographic characteristics between cases and controls was 
performed by using conditional logistic regression. We evaluated trends in Tdap vaccine 
status by birth year using the Cochran-Armitage test. All analyses were conducted in SAS 
software, version 9.3 (SAS Institute, Cary, NC).
RESULTS
During the study period, 1153 pertussis cases among adolescents were reported in 
Washington. Of those, 959 were reported in the 7 participating counties, representing 83% of 
all Washington adolescent cases and 73% of all Washington providers reporting adolescent 
cases. Pertussis incidence for this age group was 182.3 per 100 000 persons during the study 
period.
Data were collected for 887 cases and 2599 matched controls. Data were not collected for 72 
cases for the following reasons: a provider was not available for the patient (n = 45; 63.4%), 
the provider refused to participate (n = 14; 19.7%), or the provider was located outside the 
participating counties (n = 12; 16.9%). An additional 51 cases (5.8%) and 277 controls 
(10.7%) were excluded from the analysis (Table 1). The final analysis included 836 cases 
and 2322 controls. Of the 836 cases, 656 (78.5%) were classified as confirmed, 92 (11.0%) 
as probable, and 88 (10.5%) as suspect.
Table 2 lists demographic and vaccine characteristics of the cases and controls included in 
the analysis. The median age among study participants was 14 years; 54% were born 
between 1998 and 2000. Cases were more likely to be white (P = .003) and non-Hispanic (P 
= .03) than controls; however, a substantial amount of race and ethnicity data was not 
documented in the medical records and therefore was unknown. Although 74% of cases and 
75% of controls had 5 documented doses for the childhood series, only 60% of cases and 
58% of controls had a 5-dose series that was on schedule. Brand was identified by lot 
number for 25% to 29% of the childhood doses administered, depending on the dose 
number. Although documentation of childhood series lot numbers was limited, all childhood 
vaccines administered in study participants during 1998 or later with available lot numbers 
were confirmed to be acellular pertussis vaccines.
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Eighty-one percent of cases and 90% of controls were vaccinated with Tdap, and both had 
similar ages at vaccination and time since vaccination. Overall, >84% of study participants 
were vaccinated with Tdap at the recommended ages of 11 to 12 years.
For the primary analysis, which included only those who received acellular vaccines for the 
primary series (450 cases, 1246 controls), the overall Tdap VE estimate against pertussis 
was 63.9% (95% confidence interval [CI]: 49.7% to 74.1%) (Table 3). When these 
participants were stratified by time since Tdap vaccination, the VE within 12 months was 
73.1% (95% CI: 60.3% to 81.8%). At 12 to 23 months postvaccination, the VE estimate was 
54.9% (95% CI: 32.4% to 70.0%), and by 24 to 47 months it was 34.2% (95% CI: −0.03% 
to 58.0%). Subgroup analyses limited to confirmed cases or those with on-schedule 
childhood vaccinations were not substantially different from the primary analysis, with 
overlapping CIs noted (Fig 1, Supplemental Tables 5 and 6). Similarly, a subgroup analysis 
excluding those with suspect case status was not notably different from the primary analysis 
(data not shown).
The overall Tdap VE for the mixed-vaccine group (386 cases, 1076 controls) was 51.5% 
(95% CI: 26.1% to 68.1%). Because the mixed group was heavily weighted toward 
participants who received Tdap at least 3 years before study enrollment (Fig 2), Tdap 
duration of protection was stratified by less or more than 4 years since vaccination. The VE 
estimates for each of these time points were similar to the overall VE estimate, with 
overlapping CIs (<48 months: 51.5%; 95% CI: 24.3% to 69%; 48–84 months: 52.2%; 95% 
CI: 24.6% to 69.6%). Direct comparisons between the mixed group and acellular group 
could not be made for the following reasons: significant differences in the median age and 
time since vaccination between the groups (P < .0001), a greater proportion of participants 
with unknown Tdap vaccination status in the mixed group compared with the acellular group 
(7.2% vs 4.5%, respectively; P = .0007), and a significant trend of increasing unknown Tdap 
vaccination status with increasing age (Cochran-Armitage trend test, z = −6.04, P < .0001).
The Tdap product (Boostrix; GlaxoSmithKline; Adacel; Sanofi Pasteur) was verified by lot 
number in 76% of recipients (Table 2). Cases were more likely to have been vaccinated with 
Adacel compared with controls (P = .05), despite Adacel being used less frequently than 
Boostrix (17% vs 59%, respectively). Analyses of VE estimates by product were stratified 
by vaccine group. Regardless of group analyzed, Boostrix had slightly higher effectiveness 
than Adacel, although CIs overlapped (Table 4). Product-specific VE estimates in the mixed 
group were slightly lower than in the acellular group, but CIs again overlapped.
DISCUSSION
Tdap was recommended in the early 2000s to address the burden of pertussis among 
adolescents and adults.19 The preferred administration age of 11 to 12 years targeted the 
peak of disease in adolescence and supported the established adolescent vaccination 
platform. Among adolescents, national Tdap vaccine uptake has increased steadily after its 
introduction, and early evaluations indicated it was effective in reducing the adolescent 
disease burden.20–22 However, it is notable that the group of adolescents who initially 
received Tdap also received whole-cell vaccines during childhood. Despite promising 
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indicators, the number of pertussis cases among adolescents has climbed during 2012, 
mainly in 13- to 14-year-olds who received solely acellular vaccines.1 We have found that 
among adolescent recipients of all acellular vaccines, overall Tdap VE is 64%, with 
substantial waning of protection after 2 years. Although the study methodology differed 
substantially, our results were consistent with a recent Tdap VE study in Wisconsin.11 The 
waning protection revealed in both studies indicates that it likely is a major contributor to the 
increasing pertussis incidence in this age group.
Although an initial study aim was to compare Tdap VE between adolescents who received a 
mix of whole-cell and acellular vaccines with those who received all acellular vaccines, this 
was not possible due to the difference in time since vaccination between the groups. 
Seventy-seven percent of adolescents in the mixed-vaccine group received Tdap at least 3 
years before study enrollment in comparison with only 4% in the acellular vaccine group. Of 
note, however, was the finding that VE estimates in the mixed-vaccine group at less or more 
than 4 years since Tdap vaccination were similar (51.5% vs 52.2%). This finding suggests 
that durability of protection after Tdap is limited regardless of type of vaccines received 
during childhood, but that the rate of waning may be higher in those vaccinated solely with 
acellular vaccines.
Reasons for more rapid waning of Tdap-induced protection in persons vaccinated with 
acellular pertussis vaccines may be related to the immunologic response to acellular 
vaccines and a potential limitation of acellular vaccines to prevent transmission. Both whole-
cell and acellular vaccines elicit pertussis-specific antibodies, which decrease after 
immunization.23,24 However, other immunologic mechanisms, such as cell-mediated 
immunity, have also been associated with protection against pertussis disease and may be 
suboptimal after vaccination with acellular vaccines.25–28 In addition, recent data from a 
novel nonhuman primate model showed that although acellular vaccines prevented 
symptomatic disease, they failed to prevent infection and transmission.29
Recently observed genetic variation in pertussis strains may also be playing a role in VE. In 
particular, the rapid emergence of pertactin-deficient pertussis strains is concerning, because 
pertactin is one of the major antigenic components of acellular pertussis vaccines.30,31 A 
recent evaluation of available isolates obtained during the Washington 2012 outbreak 
revealed that over half carried a particular mutation resulting in pertactin deficiency.30 
Because our study was not designed to measure VE against these emerging strains, further 
evaluation is needed.
Analysis of Tdap product revealed a trend toward slightly higher VE estimates with Boostrix 
as opposed to Adacel, regardless of vaccine group analyzed. However, CIs overlapped 
between Tdap product and between vaccine group. On the basis of this analysis, definitive 
conclusions cannot be drawn regarding specific Tdap product effectiveness; nevertheless, 
these trends mirror findings of the Wisconsin study, which showed higher VE with 
Boostrix.11
As with all case-control studies, unaddressed biases could influence our findings. The 
likelihood and timing of Tdap receipt are strongly correlated with age; to control for this 
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potential bias, we matched on birth year. We also matched on primary provider clinic in an 
attempt to control for differences in provider reporting and diagnostic testing practices and 
patient access to medical care. Cases were more likely to be white and non-Hispanic, but the 
large proportion of missing data limited our ability to evaluate the relevance of these 
potential demographic differences. To minimize misclassification of controls, all were 
checked against surveillance records and excluded if they had ever been reported as a 
pertussis case. Secondary analyses were also performed to confirm that inclusion of suspect 
or probable cases in the analysis, which use a less specific case definition, did not affect the 
VE estimates.
Expanding the vaccination program to include additional Tdap booster doses is unlikely to 
result in significant disease reduction given its short duration of protection and the assumed 
lower burden of disease in adults.1 A cost-effectiveness analysis of a second dose of Tdap, 
modeling a best-case scenario of VE and duration of protection, revealed only a small 
reduction in the number of cases while incurring very high costs.32 For these reasons, in 
addition to the challenges of improving adult vaccination coverage, the Advisory Committee 
on Immunization Practices has not supported a recommendation for additional Tdap doses 
for the general population.33,34 In the interim, efforts to protect infants, who are at highest 
risk of critical disease and death, should be prioritized by reinforcing the recent 
recommendation for Tdap use during each pregnancy.35
CONCLUSIONS
We showed that Tdap protection substantially wanes within 2 to 4 years; this waning is 
likely contributing to the increase in pertussis among adolescents. Advances in our 
understanding of the immunology and bacteriology of B pertussis are essential to optimize 
future prevention and control measures. However, novel pertussis vaccines that effectively 
limit infection and transmission are also likely needed to reduce the burden of pertussis 
disease in the United States.
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WHAT’S KNOWN ON THIS SUBJECT
Although waning immunity with the childhood pertussis vaccination series has been 
reported, there are limited data on duration of protection of the adolescent pertussis 
vaccine (Tdap), especially among those who have received only acellular vaccines.
WHAT THIS STUDY ADDS
This study reports that protection from Tdap wanes substantially 2 to 4 years after 
vaccination among adolescents who received all acellular vaccines during childhood. 
This waning protection is likely contributing to the increase in adolescent pertussis.
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FIGURE 1. 
Estimated Tdap duration of protection against pertussis among adolescents who received all 
acellular vaccines (birth years 1998–2000), restricted to confirmed cases or participants with 
complete and on-schedule childhood series. Acellular vaccine group: adolescents born from 
1998 to 2000, assumed to have received all acellular pertussis vaccines for the childhood 
series (cases = 450, controls = 1256). Acellular vaccine group, confirmed case status: 
adolescents born from 1998 to 2000, assumed to have received all acellular pertussis 
vaccines for the childhood series and restricted to confirmed cases and their associated 
controls (cases = 355, controls = 984). Acellular vaccine group, complete and on-schedule 
childhood series: adolescents born from 1998 to 2000, assumed to have received all acellular 
pertussis vaccines for the childhood series and restricted to cases and controls with 5 
childhood doses on schedule (cases = 288, controls = 728). A complete and on-schedule 
primary series is considered the following: doses 1 through 3 before the first birthday, dose 4 
on or after the first birthday and before the second birthday, and dose 5 on or after the fourth 
birthday and before the seventh birthday. Refer to Table 3 and Supplemental Tables 5 and 6 
for CIs for each of these time points.
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FIGURE 2. 
Time since Tdap vaccination, by vaccine group. Acellular vaccine group: adolescents born 
from 1998 to 2000, assumed to have received all acellular pertussis vaccines for the 
childhood series (cases = 450, controls = 1256). Mixed-vaccine group: adolescents born 
from 1993 to 1997, assumed to have received a mix of whole-cell and acellular pertussis 
vaccines (cases = 386, controls = 1076).
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TABLE 1
Exclusions From Analyses Estimating Tdap VE, Duration of Protection, and Brand Effectiveness Against 
Pertussis
Reason excluded Cases (n = 887) Controls (n = 2599)
Pertussis case in previous years Not applicablea 17 (0.7)
DTaP at adolescence 2 (0.2) 11 (0.4)
Tdap before age 10 5 (0.6) 7 (0.3)
Two or more Tdap doses 15 (1.7) 77 (3.0)
Tdap vaccination status unknown 29 (3.3) 165 (6.3)
Total excluded from the analyses 51 (5.8) 277 (10.7)
Data are presented as n (%).
aOnly controls were verified as to whether they had been reported as a pertussis case previously.
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TABLE 2
Demographic Characteristics of Participants Included in Analyses Estimating Tdap VE, Duration of 
Protection, and Brand Effectiveness Against Pertussis
Characteristic Cases (n = 836) Controls (n = 2322) Pc
Birth year, n (%)
 1993–1997 386 (46.2) 1076 (46.3) Not applicablea
 1998–2000 450 (53.8) 1246 (53.7)
Gender, n (%)
 Male 428 (51.2) 1191 (51.3) .80
 Female 406 (48.6) 1122 (48.3)
 Unknown 2 (0.2) 9 (0.4)
Race, n (%)
 White 304 (36.3) 570 (24.5) .003
 Other 79 (9.5) 232 (10.0)
 Unknown 453 (54.2) 1520 (65.5)
Ethnicity, n (%)
 Non-Hispanic 304 (36.4) 625 (26.9) .03
 Hispanic 79 (9.4) 217 (9.4)
 Unknown 453 (54.2) 1480 (63.7)
Childhood series vaccination, n (%)
 Complete, on-schedule seriesb 506 (60.5) 1357 (58.4) .29
Tdap vaccination status, n (%)
 No 162 (19.4) 229 (9.9) <.0001
 Yes 674 (80.6) 2093 (90.1)
Age at Tdap, median (range), y 11 (10–17) 11 (10–18) .43
Time since Tdap vaccination, median (range), mo
 Overall 33 (1–73) 31 (0–84) .02
 Birth years 1998–2000 22 (1–47) 19 (0–47) .10
 Birth years 1993–1997 44 (2–73) 45 (0–84) .16
Tdap brand, n (%)
 Adacel 136 (20.2) 342 (16.3) .05
 Boostrix 387 (57.4) 1245 (59.5)
 Unknown brand 151 (22.4) 506 (24.2)
aCases and controls were matched on birth year, and therefore no P value was calculated.
bA complete and on-schedule primary series is considered the following: doses 1 through 3 before the first birthday, dose 4 on or after the first 
birthday and before the second birthday, and dose 5 on or after the fourth birthday and before the seventh birthday.
cP values do not apply to unknown data.
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TABLE 3
Estimated Tdap VE and Duration of Protection Against Pertussis Among Adolescents Who Received All 
Acellular Vaccines (Birth Years 1998–2000)
Cases (n = 450) Controls (n = 1246) Odds Ratio (95% CI) Estimated VE (95% CI), %
No Tdap 109 154 Reference Reference
Tdap 341 1092 0.36 (0.26 to 0.50) 63.9 (49.7 to 74.1)
Time since Tdap dose
No Tdap 109 154 Reference Reference
 <12 months 69 332 0.27 (0.18 to 0.40) 73.1 (60.3 to 81.8)
 12–23 months 124 389 0.45 (0.30 to 0.68) 54.9 (32.4 to 70.0)
 24–47 months 148 371 0.66 (0.42 to 1.03) 34.2 (20.03 to 58.0)
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TABLE 4
Estimated Tdap VE Against Pertussis, by Brand and Vaccine Group
Cases Controls Odds Ratio (95% CI) Estimated VE (95% CI), %
All birth years
 n 836 2322
 Tdap-unvaccinated 162 229 Reference Reference
 Boostrix 387 1245 0.40 (0.30 to 0.52) 60.1 (47.7 to 69.6)
 Adacel 136 342 0.51 (0.37 to 0.71) 48.8 (28.8 to 63.2)
 Unknown brand 151 506 0.37 (0.27 to 0.50) 63.2 (49.9 to 73.0)
Acellular vaccine group (birth years 1998–2000)
 n 450 1256
 Tdap-unvaccinated 109 154 Reference Reference
 Boostrix 231 725 0.37 (0.27 to 0.53) 62.6 (47.4 to 73.4)
 Adacel 50 129 0.44 (0.28 to 0.71) 55.7 (29.3 to 72.2)
 Unknown brand 60 238 0.27 (0.17 to 0.42) 73.3 (58.5 to 82.8)
Mixed-vaccine group (birth years 1993–1997)
 n 386 1076
 Tdap-unvaccinated 53 75 Reference Reference
 Boostrix 156 520 0.44 (0.28 to 0.68) 56.5 (31.7 to 72.3)
 Adacel 86 213 0.61 (0.37 to 0.99) 39.2 (0.04 to 62.8)
 Unknown brand 91 268 0.49 (0.31 to 0.78) 50.6 (22.2 to 68.7)
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